Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01178892 · ClinicalTrials.gov registry record · NA

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

A NA study of Menopause and Hot Flashes, sponsored by Fred Hutchinson Cancer Center.

Completed
Registry status
NA
Development phase
355
Enrollment target
3
Study locations

NCT01178892: Completed NA study of Menopause and Hot Flashes, sponsored by Fred Hutchinson Cancer Center.

NCT01178892 is a NA study of Menopause and Hot Flashes that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 355 participants, below the 9,388-participant average among 54 other Menopause trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01178892, a NA study of Menopause and Hot Flashes, has completed, sponsored by Fred Hutchinson Cancer Center.

COMPLETED
Registry status
NA
Development phase
355 participants
Enrollment target
3
Study locations

Study Summary

This study is the second clinical trial to be conducted by the Menopause Strategies - Finding Lasting Answers for Symptoms and Health (MsFLASH) research network, a group of investigators conducting clinical trials designed to find new ways to alleviate the most common, bothersome symptoms of the menopausal transition. In this twelve-week clinical trial, 374 women aged 40-62 who are in the late menopausal transition or postmenopausal and experiencing bothersome hot flashes will be randomized to one of three behavioral intervention groups: yoga, exercise, or usual activity. All women will simultaneously be randomized to receive omega-3 supplementation or a matching placebo. The primary aims of this trial are to compare the magnitude of changes in perceived, self-reported frequency and bother of vasomotor symptoms (VMS) before and after the intervention between yoga and the usual activity comparison group, between exercise and the usual activity comparison group, and between omega-3 fatty acid supplementation or placebo. The hypotheses to be tested are: 1. Women assigned to yoga will report lower frequency and less VMS bother than women assigned to the usual activity group at the end of a 12-week study period. 2. Women assigned to aerobic exercise at moderate-vigorous intensity will report lower frequency and less VMS bother than women assigned to the usual activity group at the end of a 12-week study period. 3. Women assigned to omega-3 fatty acid supplementation will report lower frequency and less VMS bother than women assigned to the placebo group at the end of a 12-week study period. The omega-3 component of the study is double-blinded. For yoga, exercise, and usual activity, the outcomes assessors are blinded to the randomization assignments.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Omega-3
  • BEHAVIORAL Exercise
  • BEHAVIORAL Yoga
  • BEHAVIORAL Usual Activity

Study Locations (3)

California

  • Kaiser Division of Research - Oakland

Indiana

  • Indiana University - Indianapolis

Washington

  • Group Health Research Institute - Seattle

Trial Details

FieldValue
Enrollment Target 355 participants
Start Date 2010-11
Est. Completion 2012-05
Phase NA
Fred Hutchinson Cancer Center

483 total trials

What the finished NCT01178892 record still lists

NCT01178892 is an interventional study that assigns participants to a tested intervention. The registered 355 participants enrollment target is mid-sized for trials with a published cap, below the 9,388-participant average among 54 other Menopause trials with a reported enrollment target (96% lower).

The record links to 3 conditions, with Menopause appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT01178892 reports a single indexed study location in California, Indiana, Washington.

Frequently Asked Questions

What is clinical trial NCT01178892 about?

NCT01178892 is a clinical study titled "MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation". This study is the second clinical trial to be conducted by the Menopause Strategies - Finding Lasting Answers for Symptoms and Health (MsFLASH) research network, a group of investigators conducting clinical trials designed to find new ways to alleviate the most common, bothersome symptoms of the men...

What is the current status of trial NCT01178892?

This trial is currently completed. It is a NA study. The enrollment target is 355 participants. The study started on 2010-11. Estimated completion is 2012-05.

What conditions does trial NCT01178892 study?

This clinical trial studies the following conditions: Menopause, Hot Flashes, Vasomotor Symptoms.

What interventions are being tested in trial NCT01178892?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Omega-3 (DIETARY_SUPPLEMENT), Exercise (BEHAVIORAL), Yoga (BEHAVIORAL), Usual Activity (BEHAVIORAL).

Who is sponsoring clinical trial NCT01178892?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01178892 being conducted?

This trial has 3 study locations across California, Indiana, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Menopause

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01178892's enrollment target sits among peer trials

355 6th of 54 higher than 49 of 54 other Menopause trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07133308 · 355 participants · Phase 3

    Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

  • NCT07193511 · 355 participants · Phase 1

    BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

  • NCT06077838 · 356 participants · NA

    RELAXaHEAD for Headache Patients (Phase III)

  • NCT06293469 · 356 participants · NA

    Accelerated Flap Coverage in Severe Lower Extremity Trauma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01178892, the US trial registry maintained by the National Library of Medicine. NCT01178892 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.